Dr Lisa Philp

Dr Philp is the leader of the Translational Adipokine Research group, within the Australian Prostate Cancer Research Centre - Queensland (APCRC-Q), based at the Translational Research Institute, Woolloongabba. As a trained physiologist and pharmacologist, she has over 13 years experience in animal modelling of human disease, and whole-body and molecular characterisation of phenotype and responsiveness to drug. Since joining the APCRC-Q in 2014, Dr Philp's work investigating the key role of adipokines in prostate cancer progression contributed to that of a large multi-disciplinary team of researchers at the APCRC-Q investigating the Adaptive Response to Targeting the Androgen Axis –A Strategic Offensive on Resistance in Prostate Cancer, that saw $6.25M funding awarded between 2014-2019 through a Movember Revolutionary Team Award. Her work demonstrating the importance of the adiponectin axis in prostate cancer progression, and the potent efficacy of targeting adiponectin signalling to halt tumour progression has seen her team most recently receive funding through a US Department of Defense Prostate Cancer Research Program - Idea Award of $US853896 (2020-2023). She was also recently awarded a 2020 Advance Queensland Industry Research Fellowship (AU$150,000) for her project "Preventing the respiratory failure causing COVID-19 mortality, potent new drugs targeting hyperinflammation". Through this work, Dr Philp has strong industry linkages with two independent biotech/pharmaceutical companies based in the US, and collaborations with clinicians scientists and hospital partners. Current projects are focused on the preclinical development of drugs, targeting adipokine signalling, in a quest to prevent disease, including prostate cancer progression to treatment resistance and acute respiratory distress syndrome. These projects include: 1. Restoring the adiponectin axis as a novel prostate cancer therapy. 2. Targeting the dysregulation of leptin to combat treatment resistance in advanced prostate cancer. 3. Exploring the ying-yang of adipokines in human disease. 4. Preventing the respiratory failure causing COVID-19 mortality, potent new drugs targeting hyperinflammation.  

Title

Adaptive Response to Targeting the Androgen Axis: A Strategic Offensive on Resistance (Stage 2)

Primary fund type

CAT 1 - Australian Competitive Grant

Project ID

Start year

2017

Keywords